Home » Stocks » CRSP

CRISPR Therapeutics AG (CRSP)

Stock Price: $106.64 USD 5.64 (5.58%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $107.00 +0.36 (0.34%) May 14, 7:59 PM
Market Cap 8.08B
Revenue (ttm) 1.10M
Net Income (ttm) -392.30M
Shares Out 75.77M
EPS (ttm) -5.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $106.64
Previous Close $101.00
Change ($) 5.64
Change (%) 5.58%
Day's Open 101.87
Day's Range 101.82 - 108.42
Day's Volume 1,424,732
52-Week Range 58.02 - 220.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...

Other stocks mentioned: NKTX
1 week ago - Benzinga

One company is setting itself apart in a crowded field.

1 week ago - The Motley Fool

Here is what you should know about investing in these life changing technologies.

Other stocks mentioned: BNTX, CHNA, CNCR, CVAC, EDIT, IBB, MRNA ...
2 weeks ago - Zacks Investment Research

ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

2 weeks ago - GlobeNewsWire

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

2 weeks ago - GlobeNewsWire

CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.

2 weeks ago - Zacks Investment Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)-

2 weeks ago - GlobeNewsWire

The Nasdaq gained ground to start the week.

Other stocks mentioned: SWKS
2 weeks ago - The Motley Fool

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other stocks mentioned: AXSM, QURE, VYGR, RVPH
2 weeks ago - Benzinga

BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) --  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the Europe...

2 weeks ago - GlobeNewsWire

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.

3 weeks ago - Zacks Investment Research

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

3 weeks ago - Zacks Investment Research

Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.

Other stocks mentioned: SHOP
3 weeks ago - The Motley Fool

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...

Other stocks mentioned: KALV, SNDX
3 weeks ago - Benzinga

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-

3 weeks ago - GlobeNewsWire

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Other stocks mentioned: EDIT, NTLA
1 month ago - InvestorPlace

And they all have one key thing in common.

Other stocks mentioned: REGN, TSLA, VRTX
1 month ago - The Motley Fool

ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

1 month ago - GlobeNewsWire

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, ALXN, AZN, BIIB, BNTX, EDIT ...
1 month ago - Investors Business Daily

Old crystal balls for viewing fiscal discipline never foresaw this golden age of tech innovation and ultra-low inflation.

Other stocks mentioned: ALGN, NVDA, SQ, TSLA
1 month ago - Zacks Investment Research

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other stocks mentioned: BEAM, CLLS, EDIT, NTLA
1 month ago - InvestorPlace

Last month, we talked about why investors may want to wait for better levels to enter into the CRSP stock. Since then, the stock has seen a correction of over 28%.

1 month ago - Forbes

CRISPR Therapeutics AG (CRSP) closed at $114.60 in the latest trading session, marking a -0.82% move from the prior day.

1 month ago - Zacks Investment Research

These companies may represent the future, but their stocks are getting pummeled in the present.

Other stocks mentioned: PRLB
1 month ago - The Motley Fool

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $131.10, marking a +0.41% move from the previous day.

1 month ago - Zacks Investment Research

It's a firm maybe.

1 month ago - The Motley Fool

Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.

2 months ago - InvestorPlace

Tesla's great, but these Cathie Wood favorites have even better growth prospects.

Other stocks mentioned: TDOC
2 months ago - The Motley Fool

With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.

2 months ago - InvestorPlace

ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

2 months ago - GlobeNewsWire

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...

Other stocks mentioned: BEAM, BLUE, EDIT, NTLA
2 months ago - InvestorPlace

Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount. The post Why CRSP Stock Is a Less Dicey Risk Asset Today appea...

2 months ago - InvestorPlace

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $114.65, marking a -0.73% move from the previous day.

2 months ago - Zacks Investment Research

Yields are on the rise and valuation-propelled tech is getting deflated.

Other stocks mentioned: ROKU, SQ, TDOC, TSLA
2 months ago - Zacks Investment Research

One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.

2 months ago - The Motley Fool

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

Other stocks mentioned: BMRN, GE, ANTM, AOUT, AWK, SCHW, WPM ...
2 months ago - 24/7 Wall Street

The companies with game-changing technology are often the best growth picks.

Other stocks mentioned: CCIV, SPCE
2 months ago - The Motley Fool

These stocks made investors a lot of money in 2020. Which one will be the better choice this year?

Other stocks mentioned: FLGT
2 months ago - The Motley Fool

Overvalued stocks are easy to find using metrics which indicate a stock should trade for less. But these ones keep bucking their critics.

Other stocks mentioned: AAPL, DOCU, PLUG, TSLA, VEEV, ZM
2 months ago - InvestorPlace

A few months back we talked about why the rally in CRSP stock may continue given the positive developments around CTX001, an experimental gene therapy for people with sickle cell disease and transfusion...

2 months ago - Forbes

Investors have done great in ARKK, but buying these three ARK Innovation stocks with hedged strategies is today's smart money trade. The post 3 ARK Innovation Stocks to Buy Right Now appeared first on I...

Other stocks mentioned: PSTG, SPOT
2 months ago - InvestorPlace

We are glad to announce that we have added Catherine Wood (Trades, Portfolio)'s ARK Investment Management as one of our Premium Gurus.

Other stocks mentioned: ROKU, SQ, TDOC, TSLA
2 months ago - GuruFocus

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

2 months ago - Zacks Investment Research

- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -

3 months ago - GlobeNewsWire

Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.

Other stocks mentioned: ABT, TDOC
3 months ago - The Motley Fool

Bear of the Day: CRISPR Therapeutics (CRSP)

3 months ago - Zacks Investment Research

CRISPR Therapeutics AG (CRSP) closed at $168.81 in the latest trading session, marking a +0.61% move from the prior day.

3 months ago - Zacks Investment Research

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate... [Read more...]

Industry
Biotechnology
IPO Date
Oct 19, 2016
CEO
Samarth Kulkarni
Employees
410
Stock Exchange
NASDAQ
Ticker Symbol
CRSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 160.18, which is an increase of 50.21% from the latest price.

Price Target
$160.18
(50.21% upside)
Analyst Consensus: Buy